Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Middle East Healthcare Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 7.30%.
Middle East Healthcare Co (SAU:4009) ROCE % Explanation
ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.
Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
(1) Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Middle East Healthcare Co (SAU:4009) has a ROCE % of 7.30% as of Mar. 2026.
Is Middle East Healthcare Co's ROCE % too high?
Middle East Healthcare Co's current ROCE % is 7.30%. The Healthcare Providers & Services industry median ROCE % is 6.41. Middle East Healthcare Co's value of 7.30% is 13.9% above this industry median. Overall, Middle East Healthcare Co has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Middle East Healthcare Co's ROCE % compare to HCA and THC?
Middle East Healthcare Co's ROCE % of 7.30% can be compared against companies in the Healthcare Providers & Services industry. The industry median ROCE % is 6.41. Middle East Healthcare Co's value of 7.30% is 13.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Healthcare Providers & Services company?
The median ROCE % among Healthcare Providers & Services companies is 6.41, based on 641 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Middle East Healthcare Co's current ROCE % of 7.30% is 13.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median ROCE % is 6.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Middle East Healthcare Co's current ROCE % is 7.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Middle East Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Middle East Healthcare Co (SAU:4009) is currently considered Possible Value Trap. The stock's GF Value™ is ﷼80.23, compared to a current price of ﷼30.28 — trading 62.3% below its estimated fair value. The current ROCE % is 7.30% and 13.9% above the Healthcare Providers & Services industry median of 6.41. Middle East Healthcare Co's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Middle East Healthcare Co (SAU:4009), the current ROCE % is 7.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Middle East Healthcare Co (SAU:4009) Overvalued in 2026?
Based on GuruFocus' analysis, Middle East Healthcare Co stock appears to be undervalued.
The current stock price of ﷼30.28 is trading 62.3% below its estimated GF Value™ of ﷼80.23.
GuruFocus considers Middle East Healthcare Co to be Possible Value Trap.
Key valuation signals for SAU:4009:
ROCE %: 7.30%
GF Value™: ﷼80.23 vs. price of ﷼30.28 (62.3% below fair value)
Industry Position: 13.9% above the Healthcare Providers & Services median
No single metric tells the full story. See the SAU:4009 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Middle East Healthcare Co is a Saudi Arabia-based company engaged in the business of managing, operating and maintaining hospitals, medical centers, educational centers, rehabilitation centers, physiotherapy, laboratories and radiology centers, pharmacies, construction, and to buy land for the purpose of constructing medical projects and to establish, manage and organize exhibitions for the company. The company's reportable segments are Inpatient Services, Outpatient Services, Pharmacy Sales and Others. The majority of revenue is derived from the Inpatient Services segment.
79GF Score
Get the complete analysis for SAU:4009
ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:4009 has been successfully added to your 
